

Dr. med. Woo Ri Chae, MSc

Curriculum Vitae

CONTACT INFORMATION

Charité – Universitätsmedizin Berlin
Department of Psychiatry and Neurosciences
Campus Benjamin Franklin
Hindenburgdamm 30
12203 Berlin, Germany
Email: woo-ri.chae@charite.de
Phone: +49-30 450 517625

ORCID: 0000-0002-6326-8333

CURRENT POSITION

05 / 2016 – present

Resident in psychiatry
Dept. of Psychiatry and Neurosciences,
Campus Benjamin Franklin
Charité – Universitätsmedizin Berlin, Germany

RESEARCH ACTIVITIES

01 / 2023 – present

Investigator
Effects of pharmacological dopamine modulation on
motivation and motor function in major depression
characterized by low-grade inflammation (MOTIVADE)

01 / 2023 – present

Fellow of the Berlin Institute of Health (BIH) - Charité Clinician
Scientist Program

10 / 2018 – present

Subinvestigator
Simvastatin add-on to Escitalopram in patients with comorbid
obesity and major depression: A multicenter, randomized,
double-blind, placebo-controlled trial (SIMCODE)

06 / 2016 – 04 / 2019

Subinvestigator
Effects of mineralocorticoid receptor stimulation on cognitive
bias and social cognition in patients with major depression
and healthy controls: what's the role of NMDA receptors?
(MISO)

09 / 2017 – 09 / 2018

Investigator
Double-blind, placebo-controlled study about the role of
noradrenaline and cortisol in decision making under risk,
spatial learning and memory, and social cognition (ENCODE)

EDUCATION AND TRAINING

10 / 2018 – 03/2021

Master of Science in Epidemiology
Berlin School of Public Health
Charité – Universitätsmedizin Berlin, Germany

06 / 2017	Doctor of Medicine (Dr. med.; magna cum laude)
09 / 2016 – 10 / 2019	Training in Cognitive Behavioral Therapy Institut für Verhaltenstherapie Berlin, Germany
10 / 2009 – 12 / 2015	Medical Studies Charité – Universitätsmedizin Berlin, Germany

ACTIVITIES IN THE SCIENTIFIC COMMUNITY

03 / 2023 – present	Member Equity, Diversity and Inclusion (EDI) working group, Young DZPG
05 / 2022 – present	Spokesperson Young DZPG (German Centre for Mental Health / Deutsches Zentrum für Psychische Gesundheit)
03 / 2022	Participation ECNP (European College of Neuropsychopharmacology) Workshop on Neuropsychopharmacology for Early Career Scientists in Europe, Nice, France
09 / 2021 – 08 / 2022	Participation Mentoring for Female Scientists and Academics at the Charité
05 / 2019 - present	Reviewer activities Translational Psychiatry, Psychological Medicine, Psychoneuroendocrinology, Journal of Neuroinflammation, Journal of Psychiatric Research, Journal of Clinical Medicine
06 / 2018	Participation ECNP School of Neuropsychopharmacology 2018, Oxford, United Kingdom

HONORS AND AWARDS

03 / 2019	Travel award Joint congress of AGNP (Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie) & DGBP (Deutsche Gesellschaft für Biologische Psychiatrie) 2019
01 / 2019	Scholarship 3. Symposium Zukunftsforum Public Health 2019
01 / 2016 – 04 / 2016	Doctoral Scholarship FAZIT-STIFTUNG, Frankfurt am Main
11 / 2014 – 01 / 2015	PROMOS Scholarship Deutscher Akademischer Austauschdienst (DAAD)

Publications

Dr. med. Woo Ri Chae, MSc

ORIGINAL AND REVIEW ARTICLES

1. **Chae, W. R.**, Baumert, J., Nübel, J., Brasanac, J., Gold, S. M., Hapke, U., & Otte, C. (2023). Associations between individual depressive symptoms and immunometabolic characteristics in major depression. *Eur Neuropsychopharmacol*, 71, 25-40. <https://doi.org/10.1016/j.euroneuro.2023.03.007>
2. Kaczmarczyk, M., Wingenfeld, K., Nowacki, J., **Chae, W. R.**, Deuter, C. E., Piber, D., & Otte, C. (2022). No influence of mineralocorticoid and glutamatergic NMDA receptor stimulation on spatial learning and memory in individuals with major depression. *J Psychiatr Res*. doi:<https://doi.org/10.1016/j.jpsychires.2022.06.016>
3. **Chae, W. R.**, Nübel, J., Baumert, J., Gold, S. M., & Otte, C. (2022). Association of depression and obesity with C-reactive protein in Germany: a large nationally representative study. *Brain, Behavior, and Immunity*, 103, 223-231. doi:<https://doi.org/10.1016/j.bbi.2022.04.024>
4. **Chae, W. R.**, Schienkiewitz, A., Du, Y., Hapke, U., Otte, C., & Michalski, N. (2022). Comorbid depression and obesity among adults in Germany: Effects of age, sex, and socioeconomic status. *J Affect Disord*, 299, 383-392. doi:<https://doi.org/10.1016/j.jad.2021.12.025>
5. Sforzini, L., Worrell, C., Kose, M., Anderson, I. M., Aouizerate, B., Arolt, V., . . . , **Chae, W. R.**, . . . , Pariante, C. M. (2021). A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. *Molecular Psychiatry*. doi:10.1038/s41380-021-01381-x
6. **Chae, W. R.**, Fuentes-Casañ, M., Gutknecht, F., Ljubez, A., Gold, S. M., Wingenfeld, K., & Otte, C. (2021). Early-onset late-life depression: Association with body mass index, obesity, and treatment response. *Comprehensive Psychoneuroendocrinology*, 8, 100096. doi:<https://doi.org/10.1016/j.cpneec.2021.100096>
7. Nowacki, J., Wingenfeld, K., Kaczmarczyk, M., **Chae, W. R.**, Salchow, P., Deuter, C. E., . . . Otte, C. (2021). Selective attention to emotional stimuli and emotion recognition in patients with major depression: The role of mineralocorticoid and glutamatergic NMDA receptors. *Journal of Psychopharmacology*, 02698811211009797. doi:10.1177/02698811211009797
8. **Chae, W. R.**, Metz, S., Pantazidis, P., Dziobek, I., Hellmann-Regen, J., Wingenfeld, K., & Otte, C. (2021). Effects of glucocorticoid and noradrenergic activity on implicit and explicit facial emotion recognition in healthy young men. *Stress*, 1-7. doi:10.1080/10253890.2021.1908255
9. Metz, S., **Chae, W. R.**, Deuter, C. E., Otte, C., & Wingenfeld, K. (2021). Effects of hydrocortisone and yohimbine on selective attention to emotional cues. *Journal of Psychopharmacology*, 0269881121997100. doi:10.1177/0269881121997100
10. Otte, C., **Chae, W. R.**, Nowacki, J., Kaczmarczyk, M., Piber, D., Roepke, S., . . . Gold, S. M. (2020). Simvastatin add-on to escitalopram in patients with comorbid obesity and major depression (SIMCODE): study protocol of a multicentre, randomised, double-blind, placebo-controlled trial. *BMJ Open*, 10(12), e040119. doi:10.1136/bmjopen-2020-040119
11. Nowacki, J., Wingenfeld, K., Kaczmarczyk, M., **Chae, W. R.**, Abu-Tir, I., Deuter, C. E., . . . Otte, C. (2020). Cognitive and emotional empathy after stimulation of brain mineralocorticoid and NMDA receptors in patients with major depression and healthy controls. *Neuropsychopharmacology*. doi:10.1038/s41386-020-0777-x
12. Nowacki, J., Wingenfeld, K., Kaczmarczyk, M., **Chae, W. R.**, Salchow, P., Abu-Tir, I., . . . Otte, C. (2020). Steroid hormone secretion after stimulation of mineralocorticoid and NMDA receptors and cardiovascular risk in patients with depression. *Translational Psychiatry*, 10(1), 109. doi:10.1038/s41398-020-0789-7
13. **Chae, W. R.** & Otte C. (2020). Pharmakotherapie der Depression bei Patienten mit komorbiden Erkrankungen. *NeuroTransmitter*, 31, 42-51. doi:10.1007/s15016-019-0001-6

14. Metz, S., Waiblinger-Grigull, T., Schulreich, S., **Chae, W. R.**, Otte, C., Heekeren, H. R., & Wingenfeld, K. (2020). Effects of hydrocortisone and yohimbine on decision-making under risk. *Psychoneuroendocrinology*, *114*, 104589.
doi:<https://doi.org/10.1016/j.psyneuen.2020.104589>
15. **Chae, W. R.**, Metz, S., Weise, J., Nowacki, J., Piber, D., Mueller, S. C., . . . Otte, C. (2019). Effects of glucocorticoid and noradrenergic activity on spatial learning and spatial memory in healthy young adults. *Behav Brain Res*, *373*, 112072.
doi:<https://doi.org/10.1016/j.bbr.2019.112072>
16. **Chae, W. R.**, Nagel, J. M., Kuehl, L. K., Gold, S. M., Wingenfeld, K., & Otte, C. (2019). Predictors of response and remission in a naturalistic inpatient sample undergoing multimodal treatment for depression. *J Affect Disord*, *252*, 99-106.
doi:<https://doi.org/10.1016/j.jad.2019.04.044>
17. Aust, S., Gärtner, M., Basso, L., Otte, C., Wingenfeld, K., **Chae, W. R.**, . . . Bajbouj, M. (2019). Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder. *European Neuropsychopharmacology*.
doi:<https://doi.org/10.1016/j.euroneuro.2019.02.005>
18. **Chae, W. R.**, & Dettling, M. (2018). Schizophrenie-Ersttherapie und der Faktor Zeit. *NeuroTransmitter*, *29*(06/2018), 38-42. doi:10.1007/s15016-018-6422-9

PUBLISHED ABSTRACTS

1. **Chae, W. R.**, Baumert, J., Nuebel, J., Gold, S. M., Scheidt-Nave, C., & Otte, C. (2022). Associations among C-reactive protein, depression, and obesity in a nationally representative sample of German adults. *Neuroscience Applied*, *1*, 100028.
doi:<https://doi.org/10.1016/j.nsa.2022.100028>
2. **Chae, W. R.**, Metz, S., Pantazidis, P., Dziobek, I., Wingenfeld, K., & Otte, C. (2020). Effects of glucocorticoid and noradrenergic activity on implicit and explicit facial emotion recognition in healthy men. *Psychoneuroendocrinology*, *119*, 104929.
doi:<https://doi.org/10.1016/j.psyneuen.2020.104929>
3. **Chae, W. R.**, Casan, M. F., Gutknecht, F., Ljubez, A., Gold, S. M., Wingenfeld, K., & Otte, C. (2020). P.309 Late-life depression: How do patients with early-onset vs late-onset differ in clinical features and treatment response? *European Neuropsychopharmacology*, *31*, S52-S53. doi:<https://doi.org/10.1016/j.euroneuro.2019.12.072>
4. **Chae, W. R.**, Metz, S., Weise, J., Nowacki, J., Piber, D., Mueller, S. C., . . . Otte, C. (2019). Effects of glucocorticoid and noradrenergic activity on spatial learning and spatial memory performance in healthy young adults. *Psychoneuroendocrinology*, *107*, 14.
doi:<https://doi.org/10.1016/j.psyneuen.2019.07.037>
5. **Chae, W. R.**, Nagel, J. M., Kuehl, L. K., Gold, S. M., Wingenfeld, K., & Otte, C. (2019). P.025 Predictors of response and remission in a naturalistic inpatient sample undergoing multimodal treatment for depression. *European Neuropsychopharmacology*, *29*, S37-S38.
doi:<https://doi.org/10.1016/j.euroneuro.2019.09.091>

CONFERENCE TALKS

1. **Chae, W. R.** (2022). Der Zusammenhang von Depression und Adipositas mit C-reaktivem Protein in der deutschen Allgemeinbevölkerung. DGPPN Kongress 2022, Berlin, Germany. (*accepted*).
2. **Chae, W. R.** (2020). Epidemiologie der Adipositas bei psychischen Erkrankungen (Symposium des Referats Psychosomatik). DGPPN Kongress 2020, Berlin, Germany.

POSTER PRESENTATIONS

1. **Chae, W. R.**, Baumert, J., Nuebel, J., Gold, S. M., Scheidt-Nave, C., & Otte, C. (2022). Associations among C-reactive protein, depression, and obesity in a nationally representative

- sample of German adults. ECNP Workshop for Early Career Scientists in Europe 2022, Nice, France.
2. **Chae, W. R.**, Casan, M. F., Gutknecht, F., Ljubez, A., Gold, S. M., Wingenfeld, K., & Otte, C. (2021). Clinical features and treatment response in patients with early-onset vs. late-onset late-life depression. Nature conferences: Chronic Disease and Mental Health.
 3. **Chae, W. R.**, Metz, S., Pantazidis, P., Dziobek, I., Wingenfeld, K., & Otte, C. (2020). Effects of glucocorticoid and noradrenergic activity on implicit and explicit facial emotion recognition in healthy men. 50th Annual virtual ISPNE Conference.
 4. **Chae, W. R.**, Casan, M. F., Gutknecht, F., Ljubez, A., Gold, S. M., Wingenfeld, K., & Otte, C. (2019). Late-life depression: How do patients with early-onset vs. late-onset differ in clinical features and response to multimodal inpatient treatment? DGPPN Kongress 2019, Berlin, Germany.
 5. **Chae, W. R.**, Nagel, J. M., Kuehl, L. K., Gold, S. M., Wingenfeld, K., & Otte, C. (2019). Predictors of response and remission in a naturalistic inpatient sample undergoing multimodal treatment for depression. 32nd ECNP Congress, Copenhagen, Denmark.
 6. **Chae, W. R.**, Metz, S., Weise, J., Nowacki, J., Piber, D., Mueller, S. C., Wingenfeld, K., & Otte, C. (2019). Effects of glucocorticoid and noradrenergic activity on spatial learning and spatial memory performance in healthy young adults. 49th Annual ISPNE Conference, Milan, Italy.
 7. **Chae, W. R.**, Nagel, J. M., Kuehl, L. K., Gold, S. M., Wingenfeld, K., & Otte, C. (2019). Prädiktoren für das Therapieansprechen bei stationär behandelten Patienten mit Depression. 1. Gemeinsamer Kongress der AGNP und der DGBP, Berlin, Germany.